Search
Search Results
##search.searchResults.foundPlural##
-
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1918PDF: 844HTML: 234 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2762PDF: 799HTML: 2327 -
FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients
1111PDF: 660Html: 178 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1484PDF: 497HTML: 183 -
The labyrinth of pyrexia of unknown origin: A case of intravascular B cell lymphoma
1882PDF: 719HTML: 2433Untitled: 176Figure 1 a: 186Figure 1 b: 191Fig 1 c: 174Figure 1 d: 224 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12963PDF: 1736HTML: 4354Cover letter: 227Figure 1: 235 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3483PDF: 1532HTML: 4083 -
I INCREASED RISK OF LYMPHOMA IN MEN INFECTED WITH TUBERCULOSIS
1262PDF: 542HTML: 415 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1500HTML: 406PDF: 1004Suppl. Files: 494 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3556PDF: 829HTML: 3027Figure 1a and 1b: 174Figure 2: 182Figure 3: 204Figure 4: 181Figure 5: 187Tables 1-5: 169 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1397PDF: 556HTML: 301 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3377PDF: 1523HTML: 5970Fig1-Ag-Pil: 265Ag-Pil Fig.2: 263 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1480PDF: 863HTML: 3142 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2092PDF: 1642HTML: 806 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2181PDF: 893HTML: 365 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3579PDF: 1437HTML: 2725 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1963PDF: 1209HTML: 340 -
VITAMIN D STATUS IN THALASSEMIA MAJOR: AN UPDATE
2850PDF: 1129HTML: 2637 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
556PDF: 587Suppl. Files: 75HTML: 163 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2631PDF: 884HTML: 9064Efremov 1: 260Efremov 2: 224 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4172PDF: 1204HTML: 2111Fig.1: 232Fig. 2: 128Table 1: 229Table2: 247Table 3: 227 -
Acquired Sideroblastic Anemia: An exploratory Comparative Statistical Analysis Between Clonal and Non-clonal cases Acquired Sideroblastic Anemia
1195PDF: 694HTML: 479 -
Pidotimod in paucisymptomatic SARS-CoV2 infected patients Pidotimod in COVID-19
3285PDF: 1921HTML: 994







